Are you a parent of a child with paediatric cardiomyopathy? If so, you know first-hand that PCM is a rare and often devastating heart condition. MyClimb is a Natural History Study designed to collect and evaluate information on the course of cardiomyopathy in children and adolescents with the MYBPC3 genetic mutation.
This study is sponsored by Tenaya Therapeutics, a biotechnology company committed to discovering, developing, and delivering curative therapies that address the underlying causes of heart disease. If you would like to find out more about this study please click here.